Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilganersen (ION373) in Patients With Alexander Disease
NCT04849741Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Aug 2025
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 8
01
Overview
A Phase 3 trial of zilganersen in Alexander disease, sponsored by Ionis Pharmaceuticals. Started Jun 2021; status: active, not recruiting.
02
Drugs
zilganersen
03
Conditions
Alexander disease
Beyond the preview
Go deeper on NCT04849741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849741.